Project Grant R35NS137478
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $440,275 to The Research Foundation for the State University of New York (RF SUNY) on July 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) for a two-year project period concluding June 30, 2027. The project, "Systematic Discovery of OLIG2 Upstream Regulators for Central Nervous System Myelination," focuses on...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $614,009 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded June 15, 2025, with completion targeted for April 30, 2030. The award funds basic and translational research investigating the molecular mechanisms of oligodendrocyte myelination and...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Kenyon College a Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $454,424 grant, effective April 1, 2025 through March 31, 2028, aims to characterize the cellular and molecular mechanisms of Schwann cell demyelination and identify factors that promote peripheral remyelination using a novel larval zebrafish model. The project will test...
- Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a $877,250 Project Grant on May 6, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This exploratory research initiative, with a completion date of April 30, 2028, investigates aberrant N6-methyladenosine (M6A) methylation patterns in hippocampal neurons...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $126,122 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 7, 2025, with completion anticipated by July 31, 2027. The award funds research to elucidate the role of cyclin Y-like 1 (CCNYL1) in oligodendrocyte differentiation and...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $426,057 in funding to Duquesne University to evaluate the response of oligodendrocyte precursor cells (OPCs) during a viral infection in the developing brain. The project aims to define the protective role of juvenile immune cells in promoting OPC proliferation and the...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $544,568 on February 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This Project Grant supports basic research investigating the pathogenesis of permanent neurological disability in multiple sclerosis (MS), with performance through December 31,...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey received a $429,514 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded September 1, 2025, with completion anticipated by August 31, 2027. The research will be conducted at the institution's location in New Jersey and focuses on investigating myelin acquisition and...
- Federal Project Grant Award Summary Oregon Health & Science University received a $299,776 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 23, 2026, with completion targeted for July 5, 2027. The award funds basic neuroscience research investigating the metabolic coupling mechanisms between oligodendrocyte progenitor cells (OPCs) and...
CNS DEMYELINATION: INITIATION, PROTECTION, AND CORRECTION - PROJECT SUMMARY THE LOSS OF CNS MYELIN, WHICH IS PRODUCED AND MAINTAINED BY OLIGODENDROCYTES, IS A CRITICAL ASPECT OF A WIDE RANGE OF NEUROLOGICAL CONDITIONS AND RESULTS IN THE ALTERED ELECTROPHYSIOLOGY OF THE DAMAGED AXONAL UNIT. MOREOVER, THE RESULTING MYELIN DEBRIS IMPEDE INTRINSIC EFFORTS TO REMYELINATE THE DEMYELINATED AXONS, AND THESE DEBRIS, WHICH ARE ENGULFED BY MICROGLIA, ALSO ACTIVATE AN INNATE IMMUNE RESPONSE, LEADING TO FURTHER INFLAMMATORY CNS DAMAGE. THE STUDIES DESCRIBED IN THIS PROPOSAL ARE CENTERED ON THREE ASPECTS OF DEMYELINATION: ACTIVATION, THE PROCESS BY WHICH OLIGODENDROCYTES ARE DAMAGED; PROTECTION, THE EFFORT TO SHIELD OLIGODENDROCYTES FROM FACTORS THAT LEAD TO THEIR DYSFUNCTION AND/OR DEMISE; AND CORRECTION, THE PROCESS BY WHICH DEMYELINATED AXONS ARE REMYELINATED. THIS R35 PROPOSAL REPRESENTS A CONVERGENCE OF FOUR SEPARATE, NINDS-SUPPORTED, STUDIES CENTERED ON VARIOUS ASPECTS OF THE FUNCTION AND DYSFUNCTION OF OLIGODENDROCYTES. THIS UMBRELLA AWARD WILL ALLOW US TO FOCUS OUR ENERGY ON HOW OUR UNDERSTANDING OF OLIGODENDROCYTE BIOLOGY, GAINED THROUGH THESE AWARDS, CAN BE CHANNELED INTO A DEEPER UNDERSTANDING OF THE HARMFUL IMPACT OF DEMYELINATION ON THE CNS, AS WELL AS HOW THIS DAMAGE CAN BE REDUCED AND REPAIRED. THESE EFFORTS WILL BENEFIT FROM ACCESS TO THE INDUCIBLE, GENETIC, OLIGODENDROCYTE ABLATION MOUSE MODEL (DTA) THAT WE DEVELOPED. IN ADDITION TO PROVIDING A MODEL OF ACUTE OLIGODENDROCYTE LOSS AND DEMYELINATION FOLLOWED BY ROBUST REMYELINATION, DTA MICE DEVELOP A LATE-ONSET, AUTOIMMUNE DEMYELINATING STAGE THAT MIMICS VARIOUS ASPECTS OF PROGRESSIVE MULTIPLE SCLEROSIS. OLIGODENDROCYTE PROTECTION BY THE INTEGRATED STRESS RESPONSE (ISR) HAS BEEN A MAJOR THEME OF OUR RESEARCH EFFORTS FOR OVER TWO DECADES, AND WE WILL EXTEND THIS LINE OF RESEARCH IN THE PROPOSED STUDIES. MOREOVER, OUR FUNDED STUDIES HAVE UNCOVERED THE CRITICAL ROLE OF THE ZINC FINGER PROTEIN ZFP24, AS WELL AS THE REVERSIBLE METHYLATION OF MRNA, IN THE MOLECULAR CONTROL OF OLIGODENDROCYTE DEVELOPMENT AND FUNCTION. THESE INSIGHTS WILL BENEFIT OUR EFFORTS TO BETTER UNDERSTAND AND ENHANCE THE CNS REMYELINATION PROCESS. TOGETHER, OUR PLANNED STUDIES SHOULD SIGNIFICANTLY ADVANCE OUR UNDERSTANDING OF THE CAUSES AND CONSEQUENCES OF DEMYELINATION AND REMYELINATION, WHICH ARE OF CONSIDERABLE RELEVANCE TO A WIDE RANGE OF NEUROLOGICAL DISORDERS THAT RESULT IN DISRUPTED CNS MYELIN.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 7/17/25 | ||
| Not listed | ($24k) | 7/15/24 | ||
| Not listed | $804.5k | 5/7/24 | ||
| Not listed | $804.5k | 5/7/24 |